Shaaltiel Yoseph 4
4 · Protalix BioTherapeutics, Inc. · Filed Feb 26, 2010
Insider Transaction Report
Form 4
Shaaltiel Yoseph
DirectorExecutive VP, R&D
Transactions
- Award
Stock Options (Right to Buy)
2010-02-25+145,000→ 145,000 totalExercise: $6.90Exp: 2020-02-25→ Common Stock (145,000 underlying)
Footnotes (2)
- [F1]The options vest quarterly, in 12 equal tranches over a three-year period, commencing upon the U.S. Food and Drug Administration's marketing approval of taliglucerase alfa, if at all, and are subject to accelerated vesting upon a change in control as described in the Protalix BioTherapeutics, Inc., 2006 Stock Incentive Plan.
- [F2]Does not include options to purchase 50,000 shares of common stock at an exercise price equal to $2.65 per share that expire on February 25, 2019 and options to purchase 263,728 shares of common stock at an exercise price equal to $5.00 per share that expire on February 7, 2018.